SEC Form 4 · accession 0001457612-19-000011
GENOCEA BIOSCIENCES, INC. · GNCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pamela Carroll
Officer — SVP IMMUNO-ONCOLOGY
Period of report
Feb 7, 2019
Accepted (ET)
Feb 11, 2019 · 8:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001457612
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.54 | Feb 7, 2019 | A | 200,000 | A | — | Feb 7, 2029 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The Stock Option will vest as to 1/4th of the shares subject to the option on the first anniversary of the Grant Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of February 7, 2020 (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest).